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Original articlePLIN5 deletion remodels intracellular lipid
composition and causes insulin resistance
in muscleRachael R. Mason 1, Ruzaidi Mokhtar 1, Maria Matzaris 1, Ahrathy Selathurai 1, Greg M. Kowalski 1,
Nancy Mokbel 2, Peter J. Meikle 3, Clinton R. Bruce 1, Matthew J. Watt 1,*ABSTRACT
Defective control of lipid metabolism leading to lipotoxicity causes insulin resistance in skeletal muscle, a major factor leading to diabetes. Here,
we demonstrate that perilipin (PLIN) 5 is required to couple intramyocellular triacylglycerol lipolysis with the metabolic demand for fatty acids.
PLIN5 ablation depleted triacylglycerol stores but increased sphingolipids including ceramide, hydroxylceramides and sphingomyelin. We
generated perilipin 5 (Plin5)/ mice to determine the functional signiﬁcance of PLIN5 in metabolic control and insulin action. Loss of PLIN5 had
no effect on body weight, feeding or adiposity but increased whole-body carbohydrate oxidation. Plin5/ mice developed skeletal muscle
insulin resistance, which was associated with ceramide accumulation. Liver insulin sensitivity was improved in Plin5/ mice, indicating tissue-
speciﬁc effects of PLIN5 on insulin action. We conclude that PLIN5 plays a critical role in coordinating skeletal muscle triacylglycerol meta-
bolism, which impacts sphingolipid metabolism, and is requisite for the maintenance of skeletal muscle insulin action.
 2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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The close association between the growing epidemics of obesity and
type 2 diabetes continues to fuel interest in understanding how alter-
ations in lipid metabolism contribute to the development of insulin
resistance. An excess of fatty acids beyond the cells energy re-
quirements results in the accumulation of triacylglycerol within lipid
droplets, and the deposition of lipids in tissues other than adipose tissue
is a feature of obesity and type 2 diabetes. Skeletal muscle serves as an
important site for glucose disposal after a meal [1] and it has been
known for many years that the accumulation of intramyocellular tri-
acylglycerol predicts insulin resistance in muscle, independent of
adiposity [2e5]. However, the association is not clear cut because
highly trained endurance athletes store as much triacylglycerol in their
muscles as patients with type 2 diabetes, yet display remarkable insulin
sensitivity [6]. Thus, the matching of fatty acid ﬂux from the lipid droplet
with mitochondrial demand for fatty acid substrate may be an important
regulatory process to avoid defects in insulin action.
Both skeletal and cardiac muscle store signiﬁcant amounts of tri-
acylglycerol within intracellular lipid droplets, which are located in
close proximity to the mitochondria and endoplasmic reticulum [7].
Intracellular triacylglycerol is an important energy substrate in skeletal
[8] and cardiac muscle [9] and triacylglycerol turnover is relatively high
in muscles [9,10], which ensures a continuous substrate supply to1Biology of Lipid Metabolism Laboratory, Department of Physiology, Monash University, Clayton, Victor
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supply of fatty acids, beyond the energetic needs of the myocyte,
eventually causes insulin resistance via a diverse range of mecha-
nisms including the accumulation of lipid metabolites, maladaptive
proinﬂammatory signaling and alterations in membrane physical
properties [11]. In this context, an inability to mobilize fatty acids from
triacylglycerol [12,13] and/or increase triacylglycerol breakdown in
skeletal muscle [14], without an increase in energy demand, can result
in excessive intracellular lipid accumulation and insulin resistance.
The understanding of lipid droplet biology and the regulation of
intracellular lipid ﬂuxes have expanded in recent years with the dis-
covery of perilipin (PLIN) family members [15]. PLIN1 was ﬁrst
discovered as a lipid droplet-associated protein in white adipocytes
and is a critical regulator of lipid metabolism [16,17], and more
recently PLIN2 and PLIN5 have been shown to play major roles in liver
and cardiac metabolism, respectively [18e21]. While PLIN5 is highly
expressed in skeletal muscle [22], its role in the control of intra-
myocellular lipid trafﬁcking, substrate utilization and insulin action is
not well understood. Mild overexpression of PLIN5 via DNA electro-
transfer into the glycolytic muscle of rats increased triacylglycerol
accumulation [23], which is consistent with the general consensus that
PLIN5 plays an important role in lipid droplet accumulation [22,24,25].
While PLIN5 increased triacylglycerol accumulation, this appeared to
have no effect on skeletal muscle insulin action [26]. Intriguingly, andia, 3800, Australia 2Garvan Institute of Medical Research, Darlinghurst., New South Wales, 2006,
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perhaps paradoxically, the same authors have shown that PLIN5 may
also localize to the mitochondria, suggesting that PLIN5 might direct
fatty acids from the lipid droplet to the mitochondria for oxidation [23].
While these short-term overexpression models have provided useful
insights into PLIN5 function in muscle, the physiological signiﬁcance of
PLIN5 deletion on skeletal muscle and systemic metabolic control
remains unresolved.
In the present study, we tested the hypothesis that PLIN5 plays an
important role in regulating skeletal muscle fatty acid metabolism, and
in turn, in regulating insulin action. We have generated Plin5 deﬁcient
mice and show that PLIN5 regulates skeletal muscle triacylglycerol
ﬂux, whole-body substrate metabolism and insulin action in a tissue-
speciﬁc context.
2. METHODS
2.1. Generation of PLIN5 null mice and mouse breeding
A targeted vector containing Plin5 (NM_001013706.2; Figure 1A)
interrupted in exon 5, 6, 7 was generated by the trans-NIH Knock-OutA
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ID CSD40589, ES clone EPD0301_4_E04). Blastocysts were collected
from the mating of Balb/c mice. Cells were microinjected into the
blastocyl cavity and injected blastocysts were transferred to the uteri of
pseudopregnant CD1 female mice. To test for germline transmission,
male chimeras were bred to C57BL/6N wild type female mice. Mice
were conﬁrmed to contain the PLIN5 disrupted allele by Southern blot
analysis of KpnI digested genomic tail DNA (Figure 1B). Genomic DNA
was used for PCR. Mice were backcrossed onto a C57Bl/6 background
for 2 generations. All studies were approved by the Monash University
Animal Ethics Committee.
2.2. Mice
Heterozygous mice were mated, with male Plin5/ and Plin5þ/þ
littermates used for experiments. Mice were maintained at 22 C on a
12:12-h lightedark cycle. Mice were fed a low fat (5% energy from fat)
or high-fat diet (43% energy from fat, Specialty Feeds, WA, Australia)
and had free access to water. All experiments were performed in 4 h
fasted mice commencing at 1100 h unless otherwise stated.Plin5+/+
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Original article2.3. Assessment of whole body metabolism, body composition and
physical activity
Whole body metabolism was measured in metabolic cages (Columbus
Instruments, Columbus, OH). Mice were housed individually for 48 h
for assessment of oxygen uptake, carbon dioxide production and
physical activity. Whole body fat and lean mass were measured by
Dual Energy X-ray absorptiometry (Lunar Pixi #51042, PIXImus, WI,
USA). Running experiments were performed on an Eco 3/6 treadmill
(Columbus Instruments, Columbus, OH) as described in Ref. [27]. To
determine maximal running speed, mice ran at 10 m/min on a 5%
grade for 2 min and the speed was increased by 2 m/min until
exhaustion.
2.4. Fatty acid and glucose metabolism ex vivo
Mice were anaesthetized with isoﬂurane and kept under sedation while
the soleusmuscle was excised. Fatty acid [27] and glucose metabolism
were assessed by radiometric methods as described in Ref. [28].
2.5. Tissue lipids
Lipids were extracted [29] and triacylglycerol content determined using
the TG-GPO-PAP reagent (Cat. no. 04657594190, Roche Diagnostics,
Basel, Switzerland). Diacylglycerol and ceramide content was deter-
mined by an [32P]ATP-linked enzymatic method as previously
described in Ref. [30]. Lipidomics was performed on cell lysates as
described in Ref. [31].
2.6. Glucose tolerance tests
Mice were intraperitoneally injected with D-glucose (2 g/kg mass). Tail
blood was collected and blood glucose was determined using a
glucometer (Accu-chek, Roche, Mannheim, Germany). Plasma insulin
was determined by an in-house ELISA.
2.7. Hyperinsulinemic-euglycemic clamp studies
Mice were anaesthetized and a catheter was inserted into the jugular
vein as previously described [32]. Following ﬁve days recovery, mice
were fasted for 4 h prior to beginning the clamp. Mice were conscious
but restrained for the duration of the procedure. Blood glucose was
equilibrated with a 90 min continuous infusion of [3-3H]-glucose
(0.05 mCi/min). Hyperinsulinemic-euglycemic clamp commenced with
the increase of [3-3H]-glucose tracer to 2 mCi/min and insulin infusion
(4 mU/kg/min). Exogenous glucose (25% w/v) was infused to maintain
basal blood glucose levels, which averaged 8.1  0.3 mM. Tail blood
samples were collected and blood glucose was measured every 5 min.
After 120 min, a 10 mCi bolus of 2-deoxy-d-[1-14C] glucose (2-[14C]
DG; Perkin Elmer) was administered to assess tissue-speciﬁc glucose
uptake (Rg0). At the conclusion of the clamp, mice were anaesthetized
with an intravenous injection of sodium pentobarbitone (100 mg/kg iv)
and tissues rapidly dissected and snap frozen in liquid nitrogen for
analysis of 2-[14C] DG uptake.
2.8. Intravenous insulin tolerance tests
Whole body and tissue speciﬁc insulin sensitivity was assessed in
anaesthetized (2%, isoﬂurane) mice as described in Ref. [33]. Brieﬂy,
2-[1,2-3H] deoxyglucose (10 mCi) was injected intravenously with
0.5 U/kg insulin. Blood was taken from the tip of the tail at 2, 5, 10, 15
and 20 min after injection. Samples were deproteinized, spun and the
supernatant used to determine radioactivity. Blood glucose was also
determined at these time points. Animals were sacriﬁced by exsan-
guination with tissue removed quickly and tissue speciﬁc glucose
clearance was determined from total and phosphorylated 2-[1,2-3H]
deoxyglucose [33].654 MOLECULAR METABOLISM 3 (2014) 652e663  2014 The Authors. Published by Elsevier Gm2.9. Blood biochemistry
Whole blood was collected into EDTA tubes then centrifuged for 3 min
at 8000  g. Plasma free fatty acids and triacylglycerol were
determined by enzymatic colorimetric assays (Wako Chemicals,
Wako, VA, USA). High density lipoproteins (HDL) and very (VLDL) and
low density lipoproteins (LDL) were assessed by ELISA (Ab65390,
Abcam, Cambridge, UK). Plasma b-hydroxybutyrate was analyzed by
a colorimetric assay (700190, Cayman Chemicals, Ann Arbor, MI,
USA).
2.10. Immunohistochemistry
Tissues were rapidly frozen in melting isopentane after being coated in
OCT Tissue-Tek (Sakura Finetek, The Netherlands). Serial 10 mm
sections were cut at 20 C on to SuperFrost Ultra Plus glass slides.
Slides were ﬁxed in Bouin’s solution with 0.1% Triton X-100 (Sigmae
Aldrich) for 30 min. Sections were stained for lipid droplets with freshly
made, ﬁltered oil red O (SigmaeAldrich) made in 60% triethylphos-
phate (SigmaeAldrich). b-galactosidase expression was identiﬁed
using commercial reagents (MIR 2600, Mirus Bio, Madison, WI, USA).
Sections were blocked in PBS with 1% BSA for 1 h then incubated
overnight with PLIN5 antibody (Cat. no. GP31, Progen Biotechnik,
Germany,w0.02 mg/ml) while mitochondrial staining was performed
using the mitochondrial antibody directed against the oxidative phos-
phorylation complexes IeV (Total OXPHOS Cat. no. ab110413, Abcam,
Cambridge, UK). For negative controls, primary antibodies were
substituted for concentration matched guinea pig serum for PLIN5
(Antibodies Australia), or OXPHOS cocktail pre-absorbed 4:1 overnight
with mouse IgG1 and IgG2a (Dako, Denmark). Immunohistochemistry
images were analyzed for colocalization with ImageJ (NIH) by using
Manders’ colocalization coefﬁcient, M2, which provides a fraction of
the colocalizing objects in the images. Electron microscopy was per-
formed as described previously in Ref. [34].
2.11. qRT-PCR
Total RNA was extracted, reverse transcribed and cDNA used for qRT-
PCR as described in Ref. [31]. TaqMan Gene Expression Assays are
listed in Supplementary Table 1.
2.12. Immunoblot analysis
Immunoblot analysis was performed as described previously in Ref.
[35]. Stain-free images were collected after transfer for loading control
(ChemiDoc MP and ImageLab software Version 4.1, Bio-rad Labora-
tories, NSW, Australia). Membranes were probed with commercial
antibodies (Supplementary Table 2).
2.13. Measurement of oxidative stress
Thiobarbituric acid reactive substances (TBARS) was measured in
skeletal muscle lysates by using a colorimetric assay for the formation
of malondialdehyde (10009055, Cayman Chemicals, Ann Arbor, MI,
USA).
2.14. In vitro phosphorylation
Recombinant HA-tagged murine PLIN5 was phosphorylated by cAMP-
dependent protein kinase (PKA) as described in Ref. [35] and the
location of the HA-PLIN5 was conﬁrmed by immunoblot.
2.15. Cell culture and mitochondrial metabolism
Primary myoblasts were isolated using the explant culture method
[36]. Myoblasts were differentiated to myotubes by switching to 3%
horse serum medium and were left to differentiate for ﬁve days prior to
experiments. Fatty acid metabolism (radiometric methodology) wasbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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assessed as described in Ref. [35] and mitochondrial function using
the Seahorse XF analyzer.
2.16. Statistics
Data are expressed asmeans SEM. Statistical analysiswas performed
by one-way or two-way analysis of variance (ANOVA) with repeated
measures, and speciﬁc differences were located using a Bonferroni
post hoc test. Unpaired t-tests were used where appropriate (GraphPad
Prism Version 5.02). Statistical signiﬁcance was set a priori at P 0.05.
3. RESULTS
3.1. Generation of PLIN5 deﬁcient mice
Interbreeding of heterozygous mice for the Plin5 null allele yielded mice
that were homozygous for each of the two alleles. The absence of the
Plin5 allele was conﬁrmed by Southern blotting (Figure 1B) and the
absence of PLIN5 mRNA was conﬁrmed by PCR (Figure 1C). The
absence of PLIN5 protein was conﬁrmed with immunohistochemistry
of skeletal muscle (Figure 1D). A secondary conﬁrmation was the
presence of the lacZ in the hearts of Plin5/ mice, as detected by
b-galactosidase staining (Figure 1D). Triacylglycerol content was
reduced by 52% in the hearts of Plin5/ mice (Figure 1E) and coin-
cided with a marked reduction of lipid droplets stained by ORO
(Figure 1F). This is consistent with the prominent reduction in cardiac
lipid content reported in another line of Plin5/ mice [20]. There was
no such reduction in triacylglycerol content in the liver or mixed skeletal
muscle (Figure 1F). Interestingly, triacylglycerol content was lower in
red quadriceps (oxidative) muscle and tended (122%, P < 0.08) to be
higher in white quadriceps (glycolytic) muscle of Plin5/ compared
with Plin5/ mice (Figure 1F). This may reﬂect the greater capacity of
oxidative ﬁbers to oxidize triglyceride-derived fatty acids compared
with glycolytic ﬁbers [37]. While the deletion of one Plin gene can
induce compensatory increases in the other Plin genes [20,38], the
expression of Plin 2, 3 and 4 were not altered in Plin5/ mice
(Figure 1G), nor were there changes in the expression of prominent
lipases or co-activator proteins associated with triacylglycerol lipolysis
(Figure 1G, H). Plin1 was not detected in skeletal muscle.
3.2. Whole body fatty acid oxidation is decreased in the absence of
PLIN5
Plin5þ/þ and Plin5/ mice had similar body weights during devel-
opment (Figure 2A) and DEXA examination revealed no difference in
lean and fat mass (Figure 2B). This was supported by post mortem
examination showing no difference in epididymal fat, heart and liver
mass, indicating that the absence of PLIN5 had no effect on adiposity
and gross morphology (Table 1). Neither food intake (Figure 2C) nor
energy expenditure (VO2) was different between genotypes (Figure 2D).
However, the respiratory exchange ratio was increased in Plin5/
mice (Figure 2E), demonstrating an w11% decrease in whole-body
fatty acid oxidation and a reciprocal increase in carbohydrate oxida-
tion. These changes cannot be attributed to increased physical activity
(Figure 2F). Fasting muscle and liver glycogen (Figure 2G), plasma
glucose and insulin concentrations were not different between groups;
neither were plasma free fatty acids, triacylglycerols and HDL or VLDL/
LDL cholesterol levels (Table 1). Plasma ß-hydroxybutyrate, a marker
of liver fatty acid oxidation, was not altered by genotype (Table 1).
3.3. Effects of PLIN5 deletion on skeletal muscle substrate
metabolism
Based on the high abundance of PLIN5 in skeletal muscle [22] and the
quantitative importance of skeletal muscle in regulating whole-bodyMOLECULAR METABOLISM 3 (2014) 652e663  2014 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.comsubstrate metabolism [39], we next examined the effects of PLIN5
deletion on skeletal muscle fatty acid metabolism in isolated soleus
muscle. Total fatty acid uptake, fatty acid oxidation and the incorpo-
ration of fatty acids into tri- and diacylglycerol were not different be-
tween the two genotypes (Figure 3AeD). ß-adrenergic activation of
PKA is a major regulator of triglyceride metabolism in adipocytes and
most likely oxidative skeletal muscle [37,40,41], although PKA action in
muscle requires further conﬁrmation. We ﬁrst performed in vitro kinase
assays to demonstrate that PLIN5 is a substrate for protein kinase A
(Figure 3E), then we examined fatty acid metabolism in response to
forskolin, an activator of cAMP/PKA signaling. Forskolin reduced fatty
acid uptake, oxidation and storage; however, these effects were not
impacted by Plin5 deletion. Thus, PLIN5 deletion does not affect the
uptake, oxidation or esteriﬁcation of extracellular-derived fatty acids in
muscle under basal and PKA-stimulated conditions. Further studies in
isolated soleus muscle revealed no difference in glucose oxidation
between Plin5þ/þ and Plin5/ mice (104  5 vs. 105  5 nmol/mg
tissue/h, respectively. P ¼ 0.92, n ¼ 8 per genotype).
PLIN5 interacts with ATGL to inhibit spontaneous and ß-adrenergic
stimulated lipolysis [42], suggesting that PLIN5 is more likely to
regulate fatty acid ﬂux from endogenous triacylglycerol stored in lipid
droplets rather than modulate the oxidation of extracellular-derived
fatty acids [20,42]. We performed pulse-chase experiments on pri-
mary myotubes generated from the skeletal muscle of wild-type and
Plin5/ mice to evaluate triacylglycerol metabolism. Plin5 mRNA
expression was retained in myotubes generated from Plin5þ/þ mice
and was absent in Plin5/ myotubes (Figure 3F). Intracellular tri-
acylglycerol was pre-labeled with [1-14C] oleate for 4 h, then incubated
in medium without radiolabeled fatty acids for 4 h, with or without
isoproterenol. The oxidation of triacylglycerol-derived fatty acids was
increased in Plin5/ myotubes (genotype effect, P ¼ 0.009,
Figure 3G) and this coincided with increased depletion of the 14C
labeled triacylglycerol in Plin5/ myotubes (genotype effect,
P ¼ 0.02, Figure 3H). Hence, PLIN5 deletion causes degradation of
triacylglycerol in skeletal muscle. Consistent with this notion, 24 h
fasted wild-type mice stored signiﬁcant amounts of lipid in their
skeletal muscle whereas the skeletal muscle of Plin5/ mice were
devoid of marked lipid droplet staining (Figure 3I), indicating increased
intramyocelluar lipolysis and demonstrating an inability to expand the
intramyocellular triacylglycerol pool.
3.4. Mitochondrial function is normal in the skeletal muscle of
Plin5/ mice
Intramyocellular lipid droplet biology and mitochondrial biogenesis/
metabolism are linked through shared molecular signals [43] and
increasing intramyocellular triacylglycerol ﬂux is proposed to enhance
mitochondrial biogenesis, most likely via peroxisome proliferator-
activated receptor (PPAR) mediated transcriptional reprogramming
[44,45]. We ﬁrst assessed mitochondrial function in primary myotubes.
Oxygen consumption rate was not different under basal or maximally
stimulated conditions in Plin5/ vs. Plin5þ/þmyotubes (Figure 4AeD).
In line with these in vitro observations, markers of mitochondrial content
and function were conserved in skeletal muscle in vivo. The expression
of genes related to fatty acid uptake and storage (Cd36, Dgat1), fatty
acid oxidation (Cpt1b,Mcad, Pdk4) and oxidative phosphorylation (Acox,
ATP synthase, Nrf1, Ppargc1a, Tfam, UCP2) were similar in the mixed
quadriceps muscle between genotypes (Figure 4E). In support of these
observations, themaximal activities of themitochondrial enzymes citrate
synthase (CS) and ß-hydroxyacyl CoA dehydrogenase (b-HAD) were not
affected in Plin5/ mice (Figure 4F) and the maximal running capacity
of Plin5/ mice was not different from Plin5þ/þ littermates during then access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). 655
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Figure 2: Plin5 deletion does not alter growth, adiposity, or energy expenditure but does impact substrate partitioning. (A) Body mass (_, n ¼ 6e16 Plin5þ/þ, n ¼ 10e16 Plin5/). (B) Lean
mass and fat mass assessed by DEXA (_, n ¼ 10 Plin5þ/þ, n ¼ 6 Plin5/, Age ¼ 14e16 weeks). (C) Food intake (_, n ¼ 5 Plin5þ/þ, n ¼ 5 Plin5/, Age ¼ 14e16 weeks). (D)
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dark phase. (F) Total daily activity (_, n ¼ 9 Plin5þ/þ, n ¼ 5 Plin5/, Age ¼ 14e16 weeks). (G) Muscle (n ¼ 7 Plin5þ/þ, n ¼ 8 Plin5/) and liver (n ¼ 8 Plin5þ/þ, n ¼ 9 Plin5/)
glycogen content in 4 h fasted mice (_, Age ¼ 14e16 weeks).
Original articlegraded exercise test (Figure 4G). Others have suggested that PLIN5
regulates intracellular lipid ﬂuxes by physically recruitingmitochondria to
the LD surface [46]. We detected no difference in the mitochondria to
lipid droplet contact within skeletal muscle of Plin5/ and Plin5þ/þ
mice using confocal microscopy (Figure 4H, I). Electron microscopy
images supported these ﬁndings (Figure 4J).
3.5. Glucose tolerance is improved in PLIN5 deﬁcient mice
Skeletal muscle triacylglycerol accumulation is associated with insulin
resistance [3,47] yet, paradoxically; decreasing intramyocellular tri-
acylglycerol turnover can improve insulin action [27,48,49]. Therefore,
we next asked whether Plin5 deletion would impact glucose tolerance
and insulin action. Glucose tolerance was improved in Plin5/ mice
compared to wild-type mice as indicated by an attenuated blood
glucose excursion after glucose administration (Figure 5A). Plasma
insulin increased (P ¼ 0.07, main effect) mildly after glucose
administration and was not different between genotypes (P ¼ 0.26)
(Figure 5B). This suggests improved glucose effectiveness or
enhanced insulin sensitivity in Plin5/ mice.656 MOLECULAR METABOLISM 3 (2014) 652e663  2014 The Authors. Published by Elsevier Gm3.6. PLIN5 deletion exerts tissue-speciﬁc effects on insulin action
To assess whole body and tissue-speciﬁc insulin action, we performed
hyperinsulinemic euglycemic clamps on Plin5/ and wild-type mice.
Mice were clamped at 8.1  0.3 mM glucose, 398  38 pM insulin
(no differences between genotypes) and steady-state GIR was ach-
ieved in both groups (Figure 5C). The glucose infusion rate required to
maintain euglycemia was 15% lower in the Plin5/ mice (P ¼ 0.08),
indicating a strong trend towards impaired whole-body insulin action
(Figure 5D). Hepatic glucose production was 41% lower (P ¼ 0.08) in
Plin5/ vs. Plin5þ/þ mice during the clamp (Figure 5E). This was
associated with reduced expression of the gluconeogenic genes G6pc
and Pepck in livers from Plin5/ mice (Figure 5F), suggestive of
enhanced hepatic insulin sensitivity. The glucose disposal rate (GDR)
during the clamp was reduced by 22% in Plin5/ mice (Figure 5G)
and this was associated with reduced 2-deoxyglucose uptake into
mixed skeletal muscle (34%, P ¼ 0.08, Figure 5H) and reduced
muscle glycogen content after the clamp (Figure 5I). Glucose uptake
into the heart (Figure 5H) was not different between genotypes and
glucose uptake was reduced in white adipose tissue of Plin5/ micebH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Plin5D/D Plin5L/L P value
Heart mass (mg) 135.5  4.9 138.8  5.6 0.66
Liver mass (g) 1.3  0.1 1.2  0.1 0.82
Epidydimal fat mass (g) 0.78  0.1 0.77  0.1 0.98
Blood glucose (mmol/l) 8.6  0.3 8.9  0.3 0.57
Plasma insulin (pmol/l) 133  34 140  12 0.86
Plasma FFA (mmol/l) 0.66  0.07 0.72  0.06 0.56
Plasma TG (mmol/l) 1.03  0.17 1.28  0.12 0.24
Plasma HDL (mmol/l) 0.98  0.02 1.00  0.04 0.69
Plasma VLDL/LDL (mmol/l) 0.24  0.02 0.26  0.03 0.59
Plasma ß-hydroxybutyrate (mmol/l) 133  17 135  26 0.95
Table 1: Tissue weights and blood chemistry in Plin5/ and Plin5þ/þ mice fed a low-fat
diet.
Tissue masses were from mice aged 14e16 weeks. Heart (_, n ¼ 17 Plin5þ/þ, n ¼ 18
Plin5/), liver (_, n ¼ 5 Plin5þ/þ, n ¼ 3 Plin5/) and epididymal fat pad (_, n ¼ 17
Plin5þ/þ, n ¼ 18 Plin5/).
All mice were fasted for 4 h before blood sampling. n ¼ 8 for each genotype. Data are
mean  SEM.(40%, Figure 5H), although this is a quantitatively small contribution to
systemic glucose disposal. Taken together, these data show that
Plin5/ mice become insulin resistant due to reduced insulin-
stimulated glucose disposal in skeletal muscle and adipose tissue,
but maintain insulin sensitivity in the liver.A B
FE G
I
Figure 3: Effects of PLIN5 on skeletal muscle fatty acid metabolism. Fatty acid metabolism was e
incorporation into triacylglycerol and (D) fatty acid incorporation into diacylglycerol (_, Vehicle: n ¼ 12
Age ¼ 14e16 weeks). (E) Recombinant murine PLIN5 was phosphorylated by cAMP-dependent
mixture was separated by SDS-PAGE and PLIN5 identiﬁed by immunoblotting against HA (upper band
Representative of 2 independent experiments. (F) Plin5 mRNA expression in primary myotubes of Plin5
(H) the percentage reduction of the radiolabeled TAG lipid pool (n ¼ 8 for each group from 2 indep
Representative image of lipid droplets stained with oil red O in skeletal muscle of Plin5/ and Pli
MOLECULAR METABOLISM 3 (2014) 652e663  2014 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.com3.7. Evidence of altered lipid partitioning but not ER stress,
inﬂammation or oxidative stress in the skeletal muscle of PLIN5/
mice
Ceramide and diacylglycerol are widely acknowledged as key drivers of
insulin resistance [11]. Ceramide was increased by 53% in the skeletal
muscle of Plin5/ compared with Plin5þ/þ mice, whereas diac-
ylglycerol was not different (Figure 5J). Lipidomic analysis of cultured
myotubes supported this observation: ceramide (Figure 5K, L), dihy-
dro- and hexosyl-ceramides and sphingomyelin (Figure 5L) were
increased in Plin5/ myotubes, whereas other lipid types such as
phospholipids and sterols were mostly unchanged (Figure 5M). There
was no evidence for inﬂammation (JNK phosphorylation, degradation
of IKBa, TNFa and IL-6 mRNA expression), ER stress (phosphorylated
GADD34 and PERK) or oxidative stress (thiobarbituric acid reactive
substances) in the skeletal muscle of Plin5/ mice compared with
wild-type mice (data not shown).
3.8. Effects of diet-induced obesity on lipid metabolism and insulin
action in Plin5/ mice
Because obesity impacts lipid metabolism and insulin action, we next
examined the metabolic phenotype of Plin5/ mice that were fed a
high-fat diet for eight weeks. High-fat feeding increased body mass
(Figure 6A) and fat mass (Figure 6B) in mice of both genotypes. Whole-
body energy expenditure (Figure 6C), RER (Figure 6D) and dailyC D
H
xamined in isolated soleus muscle. (A) Fatty acid uptake, (B) fatty acid oxidation, (C) fatty acid
e16 Plin5þ/þ, n ¼ 15e18 Plin5/; Forskolin, n ¼ 7e12 Plin5þ/þ, n ¼ 9e12 Plin5/,
protein kinase (PKA) catalytic subunit in kinase assay buffer containing [g-32P]ATP. The protein
). The 32P-labeled PLIN5 was detected by phosphorimaging (lower band). Arrow denotes PLIN5./ and Plin5þ/þ mice. (G) Oxidation of triacylglycerol (TAG)-derived fatty acids in myotubes and
endent donor mice and two independent experiments). *Main effect for genotype, P < 0.05. (I)
n5þ/þ mice following a 4 h and 24 h fast. Scale bar ¼ 50 mm.
n access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). 657
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Figure 4: Mitochondrial capacity is not altered by PLIN5 deletion. Measures of mitochondrial capacity in Plin5/ vs. Plin5þ/þ myotubes: (A) basal mitochondrial oxygen consumption rate, (B) ATP
turnover, (C) uncoupled respiration and (D) maximal respiration (n ¼ 10 for each group obtained from three independent donor mice and three independent experiments). (E) Expression of fatty acid
uptake, storage, and oxidation genes and oxidative phosphorylation genes (_, n ¼ 4e6 Plin5þ/þ, n ¼ 5e7 Plin5/). (F) Skeletal muscle citrate synthase and ß-hydroxyacyl CoA dehydrogenase
(b-HAD) maximal enzyme activity (_, n ¼ 8 Plin5þ/þ, n ¼ 8 Plin5/). (G) Maximal running capacity assessed on a treadmill (_, n ¼ 7 Plin5þ/þ, n ¼ 12 Plin5/). The exercise intensity was
increased every minute until mice reached exhaustion. (H) Confocal images showing oil red O (lipid, red), OXPHOS (mitochondria, green) staining and the merged images in mixed quadriceps muscle.
Scale bar ¼ 50 mm. (I) The mitochondria/oil Red O colocation was not different between genotypes (_, n ¼ 3 Plin5þ/þ, n ¼ 3 Plin5/. Nine independent sections were counted per animal with an
average total of 27  2 ﬁbers per animal). (J) Electron microscopy imaging of mixed quadriceps muscle. The white arrows highlight lipid droplets and mitochondria in contact, black arrows highlight
lipid droplets not in contact with mitochondria. Scale bar ¼ 1 mm.
Original articlephysical activity (Figure 6E) were not different between Plin5/ and
Plin5þ/þ mice. There was no difference in skeletal muscle fatty acid
oxidation (Figure 6F) or incorporation into triacylglycerol (Figure 6G)
between genotypes and lipid droplet density, diacylglycerol and cer-
amide levels were similarly unaffected (data not shown). Fasting blood
glucose (Figure 6H, P ¼ 0.07) and plasma insulin (Figure 6I) were not
different between phenotypes. Glucose tolerance was markedly better658 MOLECULAR METABOLISM 3 (2014) 652e663  2014 The Authors. Published by Elsevier Gmin high-fat fed Plin5/ compared with Plin5þ/þ mice (Figure 6J).
Indeed, high-fat fed Plin5/ mice had comparable glucose tolerance
to low-fat fed Plin5þ/þ mice (Figure 6K). Differences in plasma insulin
levels did not explain the improved glucose tolerance (Figure 6L). In-
sulin sensitivity was assessed by intravenous administration of insulin
and 2-[1,2-3H] deoxyglucose. Neither whole body deoxyglucose
clearance (P ¼ 0.30) nor tissue-speciﬁc clearance into the key sites ofbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
www.molecularmetabolism.com
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Figure 5: Glucose tolerance is maintained, but insulin sensitivity is reduced in association with muscle ceramide accumulation in Plin5/ mice fed a low-fat diet. (A) Glucose tolerance of Plin5/ mice
and Plin5þ/þ littermates (_, n¼ 23 Plin5þ/þ, n¼ 22 Plin5/, Age¼ 10e17 weeks). (B) Plasma insulin in response to glucose tolerance test (_, n¼ 10 Plin5þ/þ, n¼ 7 Plin5/, Age¼ 10e
17 weeks). (C) Glucose infusion rate during the hyperinsulinemic euglycemic clamp with the steady-state period highlighted in grey shading. (D) Average glucose infusion rate during steady state (_,
n¼ 10 Plin5þ/þ, n¼ 12 Plin5/, Age¼ 13e16 weeks). (E) Hepatic glucose production during hyperinsulinemic euglycemic clamp (_, n¼ 10 Plin5þ/þ, n¼ 12 Plin5/, Age¼ 13e16 weeks).
(F) Expression of gluconeogenic genes G6pc and Pepck (_, n ¼ 9 Plin5þ/þ, n ¼ 10 Plin5/, Age ¼ 13e16 weeks). (G) Glucose disposal rate during the hyperinsulinemic euglycemic clamp (_,
n¼ 10 Plin5þ/þ, n¼ 12 Plin5/, Age¼ 13e16 weeks). (H) Uptake of 2-deoxyglucose by skeletal muscle, heart and epididymal white adipose tissue (WAT) (_, n¼ 7 Plin5þ/þ, n¼ 8 Plin5/,
Age ¼ 13e16 weeks). (I) Muscle (n ¼ 9 Plin5þ/þ, n ¼ 9 Plin5/) and liver (n ¼ 8 Plin5þ/þ, n ¼ 8 Plin5/) glycogen content following hyperinsulinemic euglycemic clamp (_, Age ¼ 13e16
weeks). *P< 0.05 vs. Plin5þ/þ. (J) Ceramide and diacylglycerol content in skeletal muscle (_, n¼ 8 Plin5þ/þ, n¼ 8 Plin5/, Age¼ 13e16 weeks). (K) Ceramide species in Plin5/ vs. Plin5þ/þ
myotubes (n¼ 6 for each group) *P< 0.05 vs. Plin5þ/þ. (L) Sphingolipids in Plin5/ vs. Plin5þ/þ myotubes (n¼ 6 for each group) *P< 0.05 vs. Plin5þ/þ. dhCer, dihydroceramide; Cer, ceramide;
MHC, monohexosylceramide; DHC, dihexosylceramide; THC, trihexosylceramide; SM, sphingomyelin. (M) Lipids were assessed by electrospray ionization-tandem mass spectrometry in Plin5/ vs.
Plin5þ/þ myotubes (n¼ 6 for each group). Alkylphosphatidylcholine (PC(O)), lysophosphatidylcholine (LPC), phosphatidylcholine (PC), alkenylphosphatidylcholine (PC(P)), phosphatidylethanolamine (PE),
alkylphosphatidylethanolamine (PE(O)), alkenylphosphatidylethanolamine (plasmalogen) (PE(P)), phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylglycerol (PG), cholesterol ester (CE) and
cholesterol (COH). *P < 0.05 vs. Plin5þ/þ.glucose disposal was different between genotypes (Figure 6M, N),
suggesting insulin-independent mechanisms may be responsible for
the improved glucose tolerance i.e. glucose effectiveness (mass action
of glucose).
4. DISCUSSION
Lipid metabolism and insulin action are intimately linked [50] and lipid
droplets stored within tissues are critical for controlling intracellular
lipid ﬂux [51]. In this regard, the highly conserved perilipin family of
proteins reside on the surface of lipid droplets and are important for
lipid droplet formation, lipolytic regulation during times of energetic
demand and protection against lipotoxicity when cells are exposed toMOLECULAR METABOLISM 3 (2014) 652e663  2014 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.coman excess of fatty acids. PLIN5 is unique among this family because it
is highly expressed in oxidative, glucoregulatory tissues such as
skeletal muscle [22], is localized to multiple intracellular locations
including the lipid droplet, endoplasmic reticulum, mitochondria and
the cytosol [52] and may regulate a dynamic interaction between the
lipid droplet and mitochondria that is proposed to be relevant to the
etiology and treatment of insulin resistance [43,46]. Uncertainty sur-
rounds the metabolic roles of PLIN5 (discussed below), partly because
most cell systems used to date poorly reﬂect the metabolic re-
quirements of the major oxidative tissues in vivo. To address this
question, we generated Plin5/ mice and examined lipid metabolism
and insulin action in skeletal muscle, a major site for fatty acid and
glucose disposal.n access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). 659
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Figure 5: (continued).
Original articleThe controversy surrounding PLIN5’s involvement in metabolism arises
from the apparently conﬂicting observations in immortalized cell lines
that PLIN5 promotes both fatty acid oxidation and storage [22] and
either increases or decreases lipolysis [24,42,53,54]. The prevailing
views with respect to lipolysis are: (1) ATGL and CGI-58 interact
separately with PLIN5 on lipid droplets to facilitate their interaction and
drive lipolysis [53,54]; or (2) PLIN5 and CGI-58 independently recruit
ATGL to lipid droplets with opposite effects, CGI-58-ATGL interactions
drive lipolysis while PLIN5 binding to ATGL inhibits lipolysis [24,42]. In
the current study, we show that PLIN5 does not inﬂuence fatty acid
transport into myotubes, fatty acid oxidation or fatty acid esteriﬁcation
into glycerolipids. However, PLIN5 ablation increases intramyocellular
lipolysis and invokes a remarkable decrease in muscle lipid droplet
content in fasted, but not fed mice. Hence, our data agree with the
interpretation that PLIN5 provides a barrier function on lipid droplets to
prevent excessive lipolysis. These novel ﬁndings in skeletal muscle
mostly agree with the previously described role of PLIN5 in the heart.
Plin5 ablation reduced lipid droplet size, which was due to increased
ATGL-mediated TAG lipolysis and, independently, an increased ca-
pacity for FA oxidation in cardiomyocytes [20]. On the other hand,
cardiac-speciﬁc overexpression of PLIN5 inhibits ATGL-mediated
lipolysis resulting in increased lipid droplet size, myocardial stea-
tosis, mild impairments in oxidative metabolism and modest cardiac
dysfunction [21,55]. Together, these studies support the view that
PLIN5 is a highly abundant protein in muscle that is required to repress
intramyocellular lipolysis. This effect is most prominent during pro-
longed nutrient deprivation, where fatty acid substrate from both
intramyocellular and adipose tissue triacylglycerol is enhanced. Hence,
PLIN5 may protect myocytes from unnecessary depletion of intra-
myocellular fuels and/or control intracellular fatty acid ﬂux to prevent
lipotoxic outcomes.
Mitochondrial dysfunction in skeletal muscle is proposed to contribute
to reduced fatty acid oxidation, lipid deposition and the development of
insulin resistance in obese individuals [56]. Indeed, such observations
have provided the impetus for developing therapeutics aimed at660 MOLECULAR METABOLISM 3 (2014) 652e663  2014 The Authors. Published by Elsevier Gmenhancing mitochondrial function and fatty acid oxidation to treat
obesity (e.g. acetyl CoA carboxylase inhibitors, AMPK activators). While
this rationale is probably oversimpliﬁed [57], emerging evidence in-
dicates that increasing fatty acid ﬂux from lipid droplets can induce
mitochondrial biogenesis, most likely via a PPAR-mediated program,
and in turn improve cell function [43e45,58]. While we demonstrated
that fatty acid oxidation from intramyocellular lipid was increased with
Plin5 deletion, mitochondrial content and function were not enhanced
in either isolated myotubes or intact skeletal muscle; exogenous fatty
acid and glucose oxidation were not enhanced in vitro and whole-body
fatty acid oxidation was actually reduced byw11% in Plin5/ mice.
The brain and skeletal muscle account forw45% of the daily energy
expenditure [59], therefore in the absence of increased glucose
oxidation in these tissues, other tissues are most likely accounting for
the decrease in systemic fatty acid oxidation and reciprocal increase in
glucose oxidation. While the effects of PLIN5 overexpression in skeletal
muscle are equivocal [23,26], overexpression of PLIN5 in cardiac
muscle reduces intracellular lipolysis and is associated with reduced
mRNA contents of oxidative phosphorylation proteins, decreased
mitochondrial enzyme activities and mildly impaired mitochondrial
respiration [21,55]. Aside from tissue speciﬁc actions, the reasons for
this apparent discrepancy are unclear. It is possible that the increase in
intramyocellular lipolysis with Plin5 deletion was insufﬁcient to drive a
PPAR transcriptional program. This possibility is supported by the
similarity in PGC1a mRNA and PGC1a target genes between Plin5/
and control mice shown here, and further supported by a recent report
in muscle-speciﬁc ATGL null and overexpressing mice showing a
dissociation of intramyocellular lipolysis, mitochondrial biogenesis and
fatty acid oxidation [60]. Alternatively, PLIN5 may modulate the cells
molecular program via direct transcription/co-activator functions,
which may be functionally redundant in Plin5/ mice.
While intramyocellular triacylglycerol accumulation is linked to insulin
resistance [2,3], emerging data now link the etiology of insulin
resistance to the uncoupling of intramyocellular lipolysis from the
cellular demand for fatty acids [14,61]. In this context, we proposedbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Figure 6: Effects of high-fat feeding on substrate metabolism and insulin action in Plin5/ mice. (A) Body mass (_, n ¼ 14 Plin5þ/þ, n ¼ 12 Plin5/). (B) Percent body fat mass assessed by
DEXA (_, n ¼ 6 Plin5þ/þ, n ¼ 10 Plin5/, Age ¼ 14e16 weeks). (C) Oxygen consumption (VO2) and (D) respiratory exchange ratio (RER) were assessed by indirect calorimetry (_, n ¼ 6
Plin5þ/þ, n ¼ 10 Plin5/, Age ¼ 14e16 weeks). (E) Total daily activity (_, n ¼ 6 Plin5þ/þ, n ¼ 9 Plin5/, Age ¼ 14e16 weeks). (F) Fatty acid oxidation and (G) fatty acid incorporation into
triacylglycerol (TAG) (_, n ¼ 8 Plin5þ/þ, n ¼ 5 Plin5/; Age ¼ 14e16 weeks). (H) Blood glucose in 4 h fasted mice (_, n ¼ 14 Plin5þ/þ, n ¼ 16 Plin5/; Age ¼ 14e16 weeks). (I) Plasma
insulin in 4 h fasted mice (_, n ¼ 7 Plin5þ/þ, n ¼ 8 Plin5/; Age ¼ 14e16 weeks). (J) Glucose tolerance (_, n ¼ 13 Plin5þ/þ, n ¼ 16 Plin5/, Age ¼ 14e16 weeks) (K) Total glucose
area under the curve (AUC) for low fat diet (LFD) and high fat diet (HFD) from the glucose tolerance test (LFD, _, n ¼ 23 Plin5þ/þ, n ¼ 22 Plin5/, Age ¼ 10e17 weeks; HFD, _, n ¼ 14
Plin5þ/þ, n ¼ 16 Plin5/, Age ¼ 14e16 weeks). *P < 0.05 vs. all other groups. (L) Plasma insulin in response to glucose tolerance test (_, n ¼ 7 Plin5þ/þ, n ¼ 7 Plin5/, Age ¼ 14e16
weeks). (M) Rate of insulin-stimulated 3H 2-deoxyglucose disappearance from the blood and (N) rate of insulin-stimulated 3H 2-deoxyglucose (DG) clearance into mixed quadriceps skeletal muscle and
white (WAT) adipose tissue (_, n ¼ 6 Plin5þ/þ, n ¼ 8 Plin5/, Age ¼ 14e16 weeks).that the increase in muscle lipolysis combined with no additional
demand for fatty acid substrate would reduce insulin sensitivity in
Plin5/ mice. Indeed, our results show that Plin5/ mice have
reduced skeletal muscle insulin sensitivity, as demonstrated during
hyperinsulinemic euglycemic clamps. This was associated with cer-
amide accumulation, which is a negative regulator of insulin signal
transduction [50]. Other complex ceramides and sphingomyelin were
increased, while phospholipids, sterol lipids and diacylglycerol were
unchanged with Plin5 deletion. Hence, fatty acids derived from
accelerated intracellular lipolysis appear to be preferentially directed
into sphingolipids, which in turn cause insulin resistance. This inter-
pretation is consistent with a recent human study demonstrating the
inverse: increased PLIN5 content, decreased muscle ceramide (not
diacylglycerol) and improved insulin sensitivity in the skeletal muscle of
endurance trained compared with obese men [62]. The reduction in
skeletal muscle insulin sensitivity in Plin5/mice is unlikely to be due
to impaired blood ﬂow and insulin delivery, secondary to impaired
cardiac function, because impairments in the cardiac function of
Plin5/ mice is not apparent until 30e38 weeks of age [20], and weMOLECULAR METABOLISM 3 (2014) 652e663  2014 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.comassessed insulin sensitivity in mice aged 16 weeks when cardiac
function is normal.
In contrast to muscle, both hepatic glucose production and the insulin
sensitive gluconeogenic gene expression were lower in Plin5/ mice
during the insulin clamp conditions, suggestive of improved hepatic
insulin sensitivity. Moreover, Plin5/ mice have normal fasting
glucose and insulin and improved glucose tolerance compared with
wild-type mice following glucose administration. This highlights the
important role of liver in maintaining glycemia under basal and post-
prandial conditions (i.e. GTT) [63,64] and suggests that the improved
hepatic insulin action compensates for the reduced peripheral insulin
sensitivity in Plin5/ mice. It is important to note that progressive
declines in muscle insulin sensitivity have no impact on glucose
tolerance in C57Bl/6 mice [32] and that glucose effectiveness is
quantitatively more important than insulin sensitivity in the determi-
nation of glucose tolerance [65]. The contribution of glucose effec-
tiveness over insulin sensitivity is more pronounced with intraperitoneal
glucose administration, which bypasses the gut and precludes an
incretin effect, thus resulting in minimal insulin secretion. Hence,n access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). 661
Original articleour glucose tolerance and insulin clamp data are concordant. The
uncoupling of muscle and liver insulin sensitivity is not without pre-
cedence either; Plin1/ mice present with a very similar phenotype
[17], although the factors governing these responses in each genotype
are unlikely to be conserved given the unique tissue expression pat-
terns of PLIN1 (adipose) and PLIN5 (muscle, liver). Understanding the
cell-speciﬁc mechanisms that mediate the dichotomy in insulin action
is beyond the scope of these studies and future work will address this
intriguing question.
PLIN5 plays a protective role in regulating lipid homeostasis in several
tissues [20e22], including skeletal muscle, and PLIN5 abundance is a
predictor of insulin sensitivity in humans [43]. We tested whether Plin5
deletion would exacerbate the insulin resistance induced by high-fat
feeding, through an inability to appropriately sequester lipids into
lipid droplets. Energy balance, substrate partitioning and muscle lipid
metabolism and storage were mostly unperturbed in Plin5/
compared with Plin5þ/þ mice with high fat feeding. Despite these
similarities, Plin5/ mice had lower blood glucose and enhanced
glucose tolerance, which was not explained by hyperinsulinemia or
enhanced insulin sensitivity in peripheral tissues. Thus, while PLIN5
acts to sequester triacylglycerol in the lipid droplet and prevent
excessive lipolysis under standard dietary conditions, the substantial
increase in lipid ﬂux associated with high-fat feeding overwhelms
the capacity to store incoming fatty acid as triacylglycerol, resulting
in an increase in lipotoxic intermediates. Under these conditions,
the contribution of PLIN5 deletion and intramyocellular lipolysis
to sphingolipid accumulation is likely to be negligible, and
insulin resistance ensues irrespective of PLIN5 deletion. Interestingly,
Plin5/ mice are protected from high-fat feeding induced glucose
intolerance, suggesting that blocking PLIN5 may be a mechanism to
improve hepatic glucose metabolism. Though at this point we cannot
deﬁne the precise mechanisms mediating this improvement, future
studies in mice with liver-speciﬁc ablation of PLIN5 should help
delineate how this occurs.
Taken together, our studies show that PLIN5 suppresses skeletal
muscle lipolysis, particularly during prolonged nutrient deprivation,
does not inﬂuence mitochondrial reprogramming and is required for
the maintenance of insulin sensitivity in skeletal muscle by preventing
ceramide production. Others have shown that PLIN5 expression is
increased by PPARa agonists, fasting, fatty acids and endurance ex-
ercise training [22,24,25,43]; situations characterized by increased
lipid ﬂux in skeletal muscle. Hence, our data support the hypothesis
that PLIN5 is required to match lipolysis of intramyocellular tri-
acylglycerol to metabolic demands, which helps to maintain insulin
sensitivity in skeletal muscle.
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